IDH2 and glioma: CRISPR-mediated strategies may help mitigate these risks while optimizing antigen targeting for therapy.367 Vorasidenib, a BBB-penetrant IDH1/2 inhibitor, significantly reduces 2-HG levels, reversing gene expression and epigenetic changes in IDH mutant gliomas, highlighting its therapeutic potential.368